1. Home
  2. CIVI vs SUPN Comparison

CIVI vs SUPN Comparison

Compare CIVI & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Civitas Resources Inc.

CIVI

Civitas Resources Inc.

HOLD

Current Price

$29.21

Market Cap

2.6B

Sector

Energy

ML Signal

HOLD

Logo Supernus Pharmaceuticals Inc.

SUPN

Supernus Pharmaceuticals Inc.

HOLD

Current Price

$45.59

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CIVI
SUPN
Founded
1999
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.6B
IPO Year
2011
2012

Fundamental Metrics

Financial Performance
Metric
CIVI
SUPN
Price
$29.21
$45.59
Analyst Decision
Hold
Strong Buy
Analyst Count
13
4
Target Price
$40.60
$63.25
AVG Volume (30 Days)
2.0M
1.1M
Earning Date
11-06-2025
11-04-2025
Dividend Yield
6.81%
N/A
EPS Growth
N/A
N/A
EPS
6.86
N/A
Revenue
$4,711,808,000.00
$681,539,000.00
Revenue This Year
N/A
$8.29
Revenue Next Year
N/A
$22.72
P/E Ratio
$4.28
N/A
Revenue Growth
N/A
4.54
52 Week Low
$22.79
$29.16
52 Week High
$55.35
$57.65

Technical Indicators

Market Signals
Indicator
CIVI
SUPN
Relative Strength Index (RSI) 54.44 43.24
Support Level $26.70 $44.37
Resistance Level $28.10 $47.00
Average True Range (ATR) 1.26 1.56
MACD 0.25 -0.02
Stochastic Oscillator 92.44 55.51

Price Performance

Historical Comparison
CIVI
SUPN

About CIVI Civitas Resources Inc.

Civitas Resources Inc is an independent exploration and production company engaged in the acquisition, development, and production of oil and associated liquids-rich natural gas in the Rocky Mountain region, in the Denver-Julesburg Basin of Colorado - DJ Basin. The company's operations are focused on developing the horizontal Niobrara and Codell formations that have a low-cost structure, mature infrastructure, production efficiencies, multiple producing horizons, multiple service providers, established reserves, and prospective drilling opportunities.

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Share on Social Networks: